DGIdb - SULINDAC Drug Record

SULINDAC chembl:CHEMBL15770 ApprovedAntineoplastic

Alternate Names:

CLINORIL
MK-231
SULINDAC
CIS-5-FLUORO-2-METHYL-1-((P-METHYLSULFINYL)BENZYLIDENE)INDENE-3-ACETIC ACID
CIS-5-FLUORO-2-METHYL-1-((4-(METHYLSULFINYL)PHENYL)METHYLENE)-1H-INDENE-3-ACETIC ACID
SULINDACUM
(Z)-5-FLUORO-2-METHYL-1-((P-(METHYLSULFINYL)PHENYL)METHYLENE)-1H-INDENE-3-ACETIC ACID
SULINDACO
CLINORIL®
chembl:CHEMBL15770
pubchem.compound:1548887
rxcui:10237
chemidplus:38194-50-2
drugbank:00605

Drug Info:

Drug Class	anti-inflammatory agents, non-steroidal
Year of Approval	1978
Drug Categories	indenes
Drug Categories	anti-inflammatory agents, non-steroidal
FDA Approval	1978
Drug Class	small molecule
Drug Indications	NSAID
Drug Groups	investigational
Drug Categories	agents causing hyperkalemia
Drug Categories	agents that produce hypertension
Drug Categories	anti-inflammatory agents, non-steroidal (non-selective)
Drug Categories	drugs causing inadvertant photosensitivity
Drug Categories	nephrotoxic agents
Drug Categories	non cox-2 selective nsaids
Drug Categories	oat1/slc22a6 inhibitors
Drug Categories	other nonsteroidal anti-inflammatory agents
Drug Categories	photosensitizing agents

(8 More Sources)

Publications:

Taylor et al., 2000, Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells., Cancer Res.
Giuliano et al., 1999, Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs., Br. J. Pharmacol.
Yip-Schneider et al., 2000, Cyclooxygenase-2 expression in human pancreatic adenocarcinomas., Carcinogenesis
Molina et al., 1999, Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs., Cancer Res.
Fosslien, 2000, Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia., Crit Rev Clin Lab Sci
Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis
Koornstra et al., 2005, Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients., Cancer Epidemiol. Biomarkers Prev.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Cheng et al., 2002, Vascular effects of COX inhibition and AT1 receptor blockade in transgenic rats harboring mouse renin-2 gene., J. Physiol. Pharmacol.
Soriano et al., 1999, Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines., Cancer Res.
Cheng et al., 2003, Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27)., Eur. J. Pharmacol.
Lim et al., 1999, Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines., Biochem. Pharmacol.
Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem
Ferner et al., 1991, The effects of enalapril and sulindac on the dermal response to substance P and neurokinin A., Br J Clin Pharmacol
van der Sloot et al., 1995, Sulindac in established experimental diabetes: a follow-up study., Can J Neurol Sci
Chaudhry et al., 1983, Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin., Biochem. Pharmacol.
Sharma et al., Topical sulindac therapy in diabetic senile cataracts: cataract-IV., Indian J Ophthalmol
Jacobson et al., 1983, Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors., Invest. Ophthalmol. Vis. Sci.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Crabbe et al., 1985, The inhibition of bovine lens aldose reductase by Clinoril, its absorption into the human red cell and its effect on human red cell aldose reductase activity., Ophthalmic Res.
Kim et al., 2006, Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta)., Carcinogenesis
Babbar et al., 2003, Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer., J. Biol. Chem.
Liou et al., 2007, Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon., Cancer Res.
Jarvis et al., 2005, Both PPARgamma and PPARdelta influence sulindac sulfide-mediated p21WAF1/CIP1 upregulation in a human prostate epithelial cell line., Oncogene
He et al., 1999, PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs., Cell
Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med
Yip-Schneider et al., Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac., J. Gastrointest. Surg.
Pyrko et al., 2006, Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo., Mol. Cancer
Jin et al., 2006, Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin., Biochem. Pharmacol.
Hata et al., 2005, Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2., Mol. Pharmacol.
Rice et al., 2004, Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites., Cancer Res.
Rice et al., 2006, Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways., Mol. Cancer Ther.
Rice et al., 2001, Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites., Cancer Res.
Rice et al., 2003, Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells., Cancer Res.
Pangburn et al., 2005, Sulindac metabolites inhibit epidermal growth factor receptor activation and expression., J Carcinog
Wilson et al., 2002, Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention., Cancer Res.
Cousido-Siah A et al., 2015, Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10., Chem Biol Interact

SULINDAC TNFRSF10A

Interaction Score: 1.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16030090

Sources:
NCI
SULINDAC AKR1B1

Interaction Score: 0.71

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
8529171 6409111 2632448 6413448 11752352 3920599

Sources:
TTD DrugBank
SULINDAC AKR1B10

Interaction Score: 0.57

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
25532697

Sources:
DrugBank
SULINDAC MAPK3

Interaction Score: 0.34

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
15548677 16546990 11245463 12566304 16138927

Sources:
DrugBank
SULINDAC FMO3

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SULINDAC APC

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
19755659

Sources:
JAX-CKB
SULINDAC PTGS1

Interaction Score: 0.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
10372826 12512695 10626810 12586211 10484067

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions
SULINDAC TAC1

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1707646

Sources:
NCI
SULINDAC PTGDR2

Interaction Score: 0.22

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
15563582

Sources:
DrugBank
SULINDAC PTGS2

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
11118042 10372826 10657949 10485483 11078056

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions
SULINDAC BIRC5

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16707021 16950207

Sources:
NCI
SULINDAC MYC

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12414619

Sources:
NCI
SULINDAC PPARD

Interaction Score: 0.11

Interaction Types & Directionality:

negative modulator (inhibitory)

Interaction Info:

PMIDs:
16418176 14506281 17409426 16091736 10555149

Sources:
DrugBank
SULINDAC RXRA

Interaction Score: 0.09

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Antagonist

PMIDs:
23434637

Sources:
DTC GuideToPharmacology
SULINDAC PIK3CA

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30683736 12654560

Sources:
NCI CIViC
SULINDAC CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SULINDAC CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SULINDAC KDM4E

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SULINDAC CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SULINDAC CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SULINDAC CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SULINDAC EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB00605

Version: 5.1.7

Alternate Names:

SULINDAC DrugBank Drug Name

38194-50-2 CAS Number

Apo-sulin Tab 150mg Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Giuliano et al., 1999, Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs., Br. J. Pharmacol.

Cheng et al., 2002, Vascular effects of COX inhibition and AT1 receptor blockade in transgenic rats harboring mouse renin-2 gene., J. Physiol. Pharmacol.

Soriano et al., 1999, Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines., Cancer Res.

TEND: SULINDAC
- Version: 01-August-2011
Alternate Names:

SULINDAC Primary Drug Name

Drug Info:

Year of Approval 1978

Drug Class anti-inflammatory agents, non-steroidal

Publications:
TdgClinicalTrial: SULINDAC
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications NSAID

Drug Class small molecule

FDA Approval 1978

Publications:

NCI: SULINDAC

Version: 14-September-2017

Alternate Names:

C850 NCI drug code

Drug Info:

Publications:

Pyrko et al., 2006, Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo., Mol. Cancer

Jin et al., 2006, Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin., Biochem. Pharmacol.

Wilson et al., 2002, Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention., Cancer Res.

DTC: SULINDAC

Version: 02-September-2020

Alternate Names:

CHEMBL15770 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem

JAX-CKB: Sulindac
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis
CIViC: SULINDAC
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med
TTD: Sulindac
- Version: 2020.06.01
Alternate Names:

D0Z5IU TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178102078
- Version: 29-September-2020
Alternate Names:

SULINDAC GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblInteractions: CHEMBL15770
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL15770
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
PharmGKB: sulindac
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Evidence Type	Actionable
Approval Status	Preclinical
Response Type	sensitive

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

Trial Name	-
Novel drug target	Established target
Mechanism of Interaction	Cyclooxygenase inhibitor

SULINDAC	DrugBank Drug Name
38194-50-2	CAS Number
Apo-sulin Tab 150mg	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

SULINDAC Drug Record

SULINDAC chembl:CHEMBL15770 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16030090

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 8529171 6409111 2632448 6413448 11752352 3920599

Sources: TTD DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 25532697

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 15548677 16546990 11245463 12566304 16138927

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical Response Type sensitive

PMIDs: 19755659

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: 10372826 12512695 10626810 12586211 10484067

Sources: TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1707646

Sources: NCI

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

PMIDs: 15563582

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs: 11118042 10372826 10657949 10485483 11078056

Sources: TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16707021 16950207

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12414619

Sources: NCI

Interaction Types & Directionality: negative modulator (inhibitory)

Interaction Info:

PMIDs: 16418176 14506281 17409426 16091736 10555149

Sources: DrugBank

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Antagonist

PMIDs: 23434637

Sources: DTC GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30683736 12654560

Sources: NCI CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Interaction Types & Directionality:

n/a

PMIDs:
16030090

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
8529171 6409111 2632448 6413448 11752352 3920599

Sources:
TTD DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
25532697

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
15548677 16546990 11245463 12566304 16138927

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
19755659

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
10372826 12512695 10626810 12586211 10484067

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
1707646

Sources:
NCI

Interaction Types & Directionality:

antagonist (inhibitory)

PMIDs:
15563582

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
11118042 10372826 10657949 10485483 11078056

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
16707021 16950207

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12414619

Sources:
NCI

Interaction Types & Directionality:

negative modulator (inhibitory)

PMIDs:
16418176 14506281 17409426 16091736 10555149

Sources:
DrugBank

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Antagonist

PMIDs:
23434637

Sources:
DTC GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
30683736 12654560

Sources:
NCI CIViC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

SULINDAC DrugBank Drug Name

38194-50-2 CAS Number

Apo-sulin Tab 150mg Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Alternate Names:

SULINDAC Primary Drug Name

Drug Info:

Year of Approval 1978

Drug Class anti-inflammatory agents, non-steroidal

Drug Info:

Drug Indications NSAID

Drug Class small molecule

FDA Approval 1978

Alternate Names:

C850 NCI drug code

Alternate Names:

CHEMBL15770 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem

Publications:

Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis

Publications:

Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med